Editor's Note Many people have reportedly been experiencing cold-like symptoms this winter, which have often been attributed to “some bug”; however, there’s a strong chance these symptoms were due to a new surge of COVID-19, Wired January 10 reports. There’s a new, large global surge in daily COVID-19 infections currently…

Read More

Editor's Note The antibody shot Nirsevimab can protect infants from hospitalization from respiratory syncytial virus (RSV). The results from the new clinical trial were published December 28 in The New England Journal of Medicine. Affecting two of three children in their first year of life, RSV causes seasonal infection and,…

Read More

Editor's Note According to a new study from the University of Michigan, a surge in multiple respiratory viruses was associated with different pediatric acute care across emergency departments (EDs) across the state. The findings appeared in JAMA Network Open on December 7. The study used data from more than 2.7…

Read More

Editor’s note Moderna’s mRNA-based RSV vaccine is effective in preventing RSV-associated lower-respiratory tract disease in adults aged 60 an older, according to randomized phase II-III trial results published December 14 in The New England Journal of Medicine. Results also confirmed the safety of a single dose of the vaccine, researchers…

Read More

Editor's Note Hospitals in Fresno County, California are operating over capacity by 20% to 40% due to a sharp rise in respiratory diseases such as flu, COVID-19 and RSV, according to a December 18 press release from the Fresno County Department of Public Health. In addition to straining resources, the…

Read More

Editor's Note The Centers for Disease Control and Prevention (CDC) is sounding the alarm regarding low vaccination rates for COVID-19 and flu for all adults, as well as low RSV vaccination rates for adults 60 and older. According to the December 14 announcement, study data show anti-virals are also being…

Read More

The healthcare sector has begun grappling with a repeat challenge this fall and winter: the simultaneous surge of three significant respiratory diseases—flu, respiratory syncytial virus (RSV), and COVID-19 among both children and adults. When these diseases collide, they constitute what experts have termed a “tripledemic,” which poses a significant strain…

Read More

Editor's Note A new vaccine for respiratory syncytial virus (RSV) has been found to be effective against a range of variants, according to an August 2023 Science Translational Medicine research article titled, "The RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically distant respiratory syncytial virus strains." This research was…

Read More

Editor's Note The Centers for Disease Control and Prevention (CDC) is hosting a new dashboard—Respiratory Virus Hospitalization Surveillance Network (RESP-NET)—that tracks hospitalization rates for laboratory-confirmed COVID-19, influenza, and Respiratory Syncytial Virus (RSV) by age, sex, race/ethnicity, state, and season. The information is based on data from a network of acute…

Read More

Editor's Note A “sharp rise” in cases of respiratory syncytial virus (RSV) this fall is worrying staff at US hospitals, who fear what may happen to the capacity of hospitals and other healthcare facilities if RSV, influenza, and COVID-19 infections peak around the same time this winter, The Washington Post…

Read More